To Avoid Projected Shortages, the US Must Produce 712,000 Additional Credentials Aligned with High-Paying Middle-Skills Occupations Annually Through 2032, Georgetown University Report Says
Washington, DC, June 24, 2025 (GLOBE NEWSWIRE) -- The US is facing shortages of middle-skills credentials (certificates and associate's degrees) that provide pathways for early-career workers to secure jobs in occupations that are high-paying for workers without a bachelor's degree. New research from the Georgetown University Center on Education and the Workforce (CEW) finds that these projected shortages present substantial opportunities for men and women of all races/ethnicities to increase attainment of credentials aligned with high-paying middle-skills occupations. High-paying middle-skills occupations for early-career middle-skills workers (ages 18–35) offer median annual earnings of more than $55,000, but just one in four of these early-career workers is in a job that meets this threshold.
Bridging the Middle-Skills Gap: Connecting a Diverse Workforce to Economic Opportunity Through Certificates and Associate's Degrees examines the projected shortages of credentials that offer pathways to high-paying middle-skills occupations across five occupational groups. CEW researchers determined that the US is facing an annual shortage of nearly 712,000 certificates and associate's degrees aligned with high-paying middle-skills occupations nationwide. These shortages, which are projected to persist at least through 2032, fall in four occupational groups: blue-collar (360,800), management and professional office (253,000), STEM (87,500), and protective services (10,600). Healthcare is the only high-paying occupational group for early-career middle-skills workers that does not face a projected national shortage of middle-skills credentials, in part because healthcare employers increasingly prefer to fill these open positions with workers who have a bachelor's degree. In healthcare occupations, better connectivity from middle-skills credentials to bachelor's degrees would offer workers more economic opportunity.
'Credential shortages are troubling because the US is in dire need of qualified workers to keep our infrastructure intact, our communities safe, and our industries at the forefront of innovation. We must do more to improve access to and boost the attainment of credentials that align with high-paying middle-skills occupations and to smooth the transition from school to employment,' said Emma Nyhof McLeod, lead author and senior policy analyst at CEW. 'Although earning an aligned credential doesn't guarantee a job in a high-paying occupation, workers with these credentials who find work in aligned lower-paying occupations still earn more than workers in lower-paying occupations that don't align with these credentials.'
The prospects of landing in a high-paying occupation are mixed. Workers with aligned credentials have the highest chance of finding a job in high-paying middle-skills STEM occupations (73%), followed by high-paying middle-skills protective services occupations (58%), high-paying middle-skills management and professional office occupations (47%), and high-paying blue-collar middle-skills occupations (37%).
The racial/ethnic and gender demographics of workers in high-paying middle-skills occupations tell a clear story. Men hold the majority of jobs in both high-paying and lower-paying middle-skills occupations in three occupational groups (blue-collar, protective services, and STEM), and white men alone hold the plurality of high-paying middle-skills jobs in four of five occupational groups: blue-collar (68%), protective services (64%), STEM (58%), and management and professional office (49%).
Women account for only 30% of high-paying middle-skills management and professional office employment, despite holding 53% of lower-paying middle-skills jobs in this occupational group. This may be because women are more likely to earn middle-skills credentials that offer pathways to lower-paying middle-skills management and professional office occupations, even as women earn the majority of all middle-skills credentials aligned with this occupational group.
Women also earn the majority of middle-skills credentials aligned with healthcare occupations and account for more than 80% of high-paying and lower-paying middle-skills employment in these occupations. White women account for the majority of workers in both high-paying and lower-paying middle-skills healthcare occupations, though they hold a larger share of high-paying than lower-paying middle-skills healthcare jobs. While men earn just 16% of middle-skills healthcare credentials, men of all races/ethnicities who earn these credentials are more likely than women of all races/ethnicities to earn them in programs that align with high-paying healthcare occupations. White men are the most likely to earn credentials that align with high-paying healthcare occupations (61%), while Black/African American women are the least likely to earn these credentials (22%).
'Credential shortages present an opportunity to diversify high-paying middle-skills occupations and strengthen the American economy by drawing qualified workers from the widest talent pool possible. But first, we need to address long-standing disparities in credential attainment and the labor market,' said co-author and CEW Director Jeff Strohl. 'Increasing the number of work-based learning opportunities, providing integrated academic and career support services, and addressing biases in hiring and promotion are necessary to clear the pathway to opportunity in high-paying middle-skills occupations.'
As described in the report, filling credential shortages more equitably would mean that, for men and women of all races/ethnicities, the new share of credentials earned aligning with high-paying occupations in each occupational group would match the current share of all credentials earned in each occupational group. Filling credential shortages equitably would require an increase of more than 500% in credentials aligned with high-paying blue-collar middle-skills occupations among men and women of all racial/ethnic backgrounds, along with substantial increases in credentials aligned with STEM, management and professional office, and protective services occupations.
To view the full report, including a more in-depth discussion of policy and practice recommendations for the high-paying middle-skills workforce, visit: https://cew.georgetown.edu/bridging-middle-skills-gap.
The Georgetown University Center on Education and the Workforce (CEW) is a research and policy institute within Georgetown's McCourt School of Public Policy that studies the links between education, career qualifications, and workforce demands. For more information, visit https://cew.georgetown.edu/. Follow CEW on X @GeorgetownCEW, Instagram, YouTube, and LinkedIn.
CONTACT: Katherine Hazelrigg Georgetown University Center on Education and the Workforce kh1213@georgetown.edu
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...
Net Loss: $33.5 million or $0.58 per share for Q1 2025, compared to $31.4 million or $0.54 per share in Q4 2024. Cash and Investments: $52.5 million as of March 31, 2025. Debt Reduction: Total debt reduced by $10 million, with near-term repayment obligations lowered from $118 million to $17 million. OMIDRIA Royalties: $6.7 million for Q1 2025 based on net sales of $22.3 million, down from $10.1 million in Q4 2024. Interest Expense: $3.7 million for Q1 2025, reflecting a $477,000 increase from Q4 2024. Operating Expenses: $35 million for Q1 2025, a decrease of $691,000 from Q4 2024. Income from Discontinued Operations: $4.1 million for Q1 2025, down $1.1 million from Q4 2024. Warning! GuruFocus has detected 2 Warning Signs with OMER. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Omeros Corp (NASDAQ:OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million. The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital. The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25. Omeros Corp (NASDAQ:OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access. The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse. Negative Points Omeros Corp (NASDAQ:OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter. The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA. There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline. OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue. Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes. Q & A Highlights Q: Can you provide details on the launch plans for narsoplimab and its impact on patient access? A: Greg Demopulos, Chairman & CEO, stated that the company is well-prepared for the launch, expecting it to be successful. Nadia Dac, Chief Commercial Officer, elaborated that the team is focused on the top 40 transplant centers responsible for 60% of the allogeneic transplant volume. They have identified key decision-makers and are engaging with payers, emphasizing narsoplimab's unique value as the only approved treatment for TA-TMA. Q: Can you provide more information about the patients affected by TA-TMA and the associated healthcare costs? A: Greg Demopulos explained that TA-TMA is an unpredictable complication of stem cell transplants, often resulting in rapid deterioration and high mortality. Nadia Dac added that untreated patients incur significant costs, such as ICU stays and organ failure treatments. Narsoplimab aims to reduce these costs by offering an effective outpatient treatment option. Q: How are you managing the financial aspects of the company, particularly regarding debt and capital raising? A: Greg Demopulos highlighted the recent exchange agreement that reduced the 2026 convertible notes' principal, lowering near-term repayment obligations by over $100 million. The company is also exploring partnerships for non-dilutive funding and has an active at-the-market facility to raise up to $150 million. Q: What are the strategic priorities for Omeros beyond narsoplimab? A: Greg Demopulos mentioned that the company is prioritizing the development of zaltenibart for paroxysmal nocturnal hemoglobinuria (PNH) and continuing its PDE7 inhibitor program for cocaine use disorder, funded by a NIDA grant. They are also advancing their oncology platform, Oncotox, targeting acute myeloid leukemia. Q: What is the current status of the narsoplimab BLA resubmission and its potential market impact? A: Greg Demopulos confirmed that the FDA has accepted the resubmitted BLA for narsoplimab in TA-TMA, with a target action date of September 25. The company anticipates narsoplimab to be the first approved therapy for TA-TMA, addressing a nearly $1 billion annual market opportunity. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
26 minutes ago
- Yahoo
Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Beeline Holdings Inc (NASDAQ:BLNE) successfully divested its spirits assets, allowing a full focus on its core digital mortgage lending business. The company reported a 27% increase in revenue and a 40% decrease in expenses in Q2 2025 compared to Q1 2025. Beeline Holdings Inc (NASDAQ:BLNE) introduced a new equity product that is not tied to interest rates, providing a competitive advantage. The AI sales agent, Bob, significantly improved lead conversion and mortgage application rates, contributing approximately $150,000 in revenue. The company reduced its debt by $6.2 million in 2025, aiming to be debt-free by November 1, 2025, and cash flow positive by January 2026. Negative Points The market remains challenging due to higher interest rates affecting refinance and purchase transactions. The company reported a net loss from continuing operations of $4 million for Q2 2025. There were $500,000 in one-time non-recurring expenses in Q2, impacting financial results. The broader launch of the new equity product has been delayed to ensure proper execution and customer satisfaction. Despite improvements, the company still faces significant scaling challenges and uncertainties in its new product offerings. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with BLNE. Q: Can you provide more details about the home equity cash-out product and the timing of its broader launch? A: (Nick Lauza, CEO) We initially planned to launch in late August or early September but decided to delay to ensure we get it right. The opportunity is massive, with untapped equity in the US market. The Genius Act provides regulatory clarity, and we want to ensure the product is perfect before scaling. We will conduct a select number of transactions over the next 30 to 45 days to gather feedback and ensure consumer interests are prioritized. Q: What are the assumptions behind your profitability projections for late this year or early next year? A: (Nick Lauza, CEO) We are focusing on achieving profitability quickly by cutting $225,000 in monthly recurring expenses, which will be fully realized by September. Our locks are up, and we've reduced our marketing budget by $40,000 monthly while maintaining strong performance. We also had $500,000 in one-time expenses in Q2, which won't recur. We aim to be debt-free by November 1 and cash flow positive by January 2026. Q: Can you explain the economics of the fractional products and the expected volume at scale? A: (Nick Lauza, CEO) Our margins will be higher than our mortgage products, with less work involved since we're underwriting the property, not the consumer. We expect about 33% more revenue per file. Marketing expenses will be minimal as our partner will drive the business. We've identified about 1,000 potential customers who would qualify for this product. Q: What will drive significant growth in 2026, even without rate cuts? A: (Nick Lauza, CEO) We expect strong demand for Beeline Equity, as it provides liquidity based on home equity rather than individual qualifications. This product is ideal for those who can't qualify for cash-out refis or HELOCs. Additionally, our mortgage business is improving, and we have a strong title business team. We anticipate the equity product to be our largest revenue generator in 2026, followed by the mortgage and title businesses. Q: Do you have a sensitivity analysis for how rate cuts could impact growth? A: (Nick Lauza, CEO) While we don't have specific figures, a 25 basis point cut would significantly impact our business as a centralized digital lender. Digital models perform better in low-rate environments, and a 1-point cut would lead to rapid growth. (Chris Moe, CFO) Additionally, the longer rates remain high, the more significant the impact of a cut due to pent-up demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Dare Bioscience Inc (NASDAQ:DARE) is on track to launch its sildenafil cream, Dare to Play, through a 503b outsourcing facility in Q4 2025, marking a significant milestone in women's sexual health. The company is advancing a differentiated clinical pipeline with grant-funded programs targeting unmet needs in contraception, HPV, and preterm birth. Dare Bioscience Inc (NASDAQ:DARE) received positive feedback from its direct-to-patient awareness campaign, highlighting significant interest in its products. The Oviprine Phase 3 trial continues as planned with no new safety concerns, supporting its potential as a hormone-free contraceptive option. The company strengthened its financial position with $17.6 million in net proceeds from stock sales and a $6 million grant payment, enhancing its ability to execute its strategy. Negative Points Dare Bioscience Inc (NASDAQ:DARE) ended the quarter with a working capital deficit of approximately $12.6 million. The company experienced a 71% decrease in R&D expenses compared to Q2 2024, primarily due to reductions in manufacturing and development costs. There were technical difficulties during the earnings call, preventing a Q&A session, which may have limited investor engagement. The company's dual path strategy involves risks associated with FDA approval processes and market acceptance of its products. Despite the progress, the company operates in a highly competitive market with significant challenges in bringing new women's health solutions to market. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with DARE. Q: What is the status of the Dare to Play Sildenafil Cream launch? A: Sabrina Martucci Johnson, President and CEO, stated that Dare Bioscience remains on track to support the commercial availability of Dare to Play Sildenafil Cream through a 503b outsourcing facility in the fourth quarter of 2025. This launch is a significant milestone for the company and the field of women's sexual health. Q: Can you provide an update on the Ovaprine Phase 3 trial? A: Sabrina Martucci Johnson explained that the Independent Data and Safety Monitoring Board reviewed interim data from the Phase 3 study and recommended that the trial continue as planned. The interim pregnancy rate was consistent with expectations, supporting Ovaprine's potential as a non-hormonal contraceptive option. Q: What is the dual commercialization pathway for DARE HRT1? A: Sabrina Martucci Johnson highlighted that DARE HRT1, an intravaginal ring for hormone therapy, is pursuing both FDA approval and a 503b compounding opportunity. This approach aims to accelerate patient access while generating necessary data for FDA approval. Q: How is Dare Bioscience expanding into consumer health products? A: Sabrina Martucci Johnson announced plans to launch two non-prescription vaginal probiotics to support vaginal microbiome health. These products will complement the prescription offerings and diversify the company's commercial platform. Q: What are the financial highlights for the second quarter of 2025? A: Marty Herringlayton, Chief Accounting Officer, reported that Dare Bioscience ended the quarter with approximately $5 million in cash and a working capital deficit of $12.6 million. Post-quarter, the company received $17.6 million from stock sales and a $6 million grant, strengthening its balance sheet. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data